

CURRICULUM VITAE

NAME Joe Lynn Williams, Jr, MD, PhD

LOCATION

1st Allergy and Asthma Center
3260 East 104th Avenue
Thornton, CO 80233
Office: 720-929-8300

1st Allergy and Clinical Research Center
7286 South Yosemite, Suite 180
Centennial, CO 80112
Office: 303-773-9000
Fax: 303-770-1449

1st Infusion Center
7286 S. Yosemite St. Ste.110
Centennial, CO 80112

LICENSE Colorado Medical License #35277

EDUCATION

1976 AA- Chemistry
Oxford College of Emory University

1979 Bachelor of Science- Biology
North Georgia College

1985 Phd- Physiology
W. Virginia University

1989 Postdoctoral Fellow
Department of Pharmacology
University of Tennessee, Memphis

1993 Medical Degree
University of Tennessee, Memphis

1996 Pediatric Residency Program
University of Colorado, Denver

POSITIONS HELD

- May 2005- present Pediatrician
1st Allergy and Asthma Center/ Thornton, CO
Child First Pediatrics/ Centennial, CO
1st Allergy and Clinical Research Center/ Centennial, CO
- June 2001- April 2005 Pediatrician
Wallace C. White, MD/ Denver, CO
- Jan 2000- June 2001 Pediatrician
Gateway Pediatrics/ Aurora, CO
- May 1999- November 1999 Pediatrician
Greenwood Pediatrics/ Englewood, CO
- July 1996- December 1998 Pediatrician
Platte Valley Pediatrics/ Scottsbluff, NE

HONORS AND SOCIETY MEMBERSHIPS

Phi Theta Kappa (National Jr. College Scholastic Society)
Phi Kappa Phi (National Honor Society)
NIH Training Grant (Hypertension study)
Tennessee Heart Association Postdoctoral Fellow
NIH Postdoctoral Fellow
Alpha Omega Alpha, Beat Chapter (National Honor Medical Society)
Diplomat of the American Board of Pediatrics
Fellow American Academy of Pediatrics
Denver Medical Society

RESEARCH EXPERIENCE

SUB-INVESTIGATOR FOR THE FOLLOWING STUDIES

2005: Pediatric (6-11) study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of an investigational drug in children with moderate-severe, persistent, inadequately controlled allergic asthma.

2005: Pediatric (6-11 yrs) study comparing the safety and efficacy of an investigational nasal spray drug in patients with seasonal allergic rhinitis.

2005: Pediatric (4-6 yrs) study to determine the safety and immunogenicity of an investigational combination vaccine, when administered as a 5th dose in this age group.

2005: Phase three, pediatric (6-14 yrs) study comparing the clinical effects of an investigational intravenous drug in patients with acute asthma.

2005: Adolescent (12-17) study comparing the safety and efficacy of an investigational drug in migraine prophylaxis.

2005: Adult (15 and up) study comparing the clinical effects of an investigational intravenous drug in patients with acute asthma.

2005: Adult (18 yrs and up) study to evaluate the relationship and impact of clinical symptoms of allergic rhinitis, on key patient reported outcomes in addition to establishing a minimally important difference in overall symptoms of allergic rhinitis, with particular regard to nasal congestion and morning allergy symptoms.

2005: Adolescent (12-17) long-term study to determine the safety of an investigational study drug in the treatment of migraines.

2006: Phase three adolescent/adult study, evaluating the safety and efficacy of an investigational drug versus penicillin in the treatment of patients with tonsillitis and/or pharyngitis secondary to streptococcus pyogenes.

2006: Phase three pediatric study (age 6 < 6 years), evaluating the safety and efficacy of an investigational drug versus penicillin in the treatment of patients with acute otitis media.

2006: Phase four adult study (age 18 yrs and up) evaluating the safety and efficacy of an investigational drug versus azithromycin in outpatients with community-acquired lower respiratory tract infections.

2006: Phase three pediatric (age 6-14) study evaluating the clinical effect of investigational drug versus placebo in patients with seasonal aeroallergen sensitivity.

2007: A study evaluating the effects of an investigational study drug in patients with mild to moderate asthma.

2007: An open label, single arm study to assess the safety and immunogenicity of a study medication administered subcutaneously over a period of 6 months to male and female adolescents and adults with moderate to severe persistent allergic asthma.

2007: A study evaluating the tolerability and pharmacokinetic comparison of study drug administered intravenously or subcutaneously in subjects with Primary Immunodeficiency Diseases.

2007: A phase III, randomized, active-control, double-blind trial evaluating the safety, tolerability and immunogenicity of a pediatric pneumococcal vaccine in healthy infants given with routine pediatric immunizations in the United States.

2007: A phase III clinical trial comparing the safety and efficacy of a combination inhaler to using the components separately or placebo in adolescent and adult patients with mild to moderate asthma.

2007: A phase IIIb exacerbation clinical trial to compare the effect of two inhaled medications given twice-daily in COPD patients.

2007: A study of the therapeutic equivalency of inhalers in corticosteroid-dependent subjects with moderate asthma.

2007: Safety study of a meningococcal vaccine when administered with other pediatric vaccines to healthy toddlers.

2007: Determination of the dose of investigational medication required enabling up to 600 mg/kg of IGIV, 10% to be administered subcutaneously in a single infusion site in patients with Primary Immunodeficiency Disease.